Revolutionizing mRNA for Life - Investor Presentation, July 2021 - CureVac
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Revolutionizing mRNA for Life Investor Presentation, July 2021
Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of Forward-looking statements are subject to many risks, uncertainties and other
the information you may desire. Statements contained herein are made as of the date variable circumstances, including negative worldwide economic conditions and
of this document unless stated otherwise, and neither the delivery of this document at ongoing instability and volatility in the worldwide financial markets, ability to obtain
any time, nor any sale of securities, shall under any circumstances create an funding, ability to conduct current and future preclinical studies and clinical trials, the
implication that the information contained herein is correct as of any time after such timing, expense and uncertainty of regulatory approval, reliance on third parties and
date or that information will be updated or revised to reflect information that collaboration partners, ability to commercialize products, ability to manufacture any
subsequently becomes available or changes occurring after the date hereof. products, possible changes in current and proposed legislation, regulations and
governmental policies, pressures from increasing competition and consolidation in the
This presentation of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG,
company’s industry, the effects of the COVID-19 pandemic on the company’s
CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac
business and results of operations, ability to manage growth, reliance on key
Corporate Services GmbH (the “company”) contains statements that constitute
personnel, reliance on intellectual property protection, ability to provide for patient
“forward-looking statements” as that term is defined in the United States Private
safety, and fluctuations of operating results due to the effect of exchange rates or
Securities Litigation Reform Act of 1995, including statements that express the
other factors. Such risks and uncertainties may cause the statements to be inaccurate
company’s opinions, expectations, beliefs, plans, objectives, assumptions or
and readers are cautioned not to place undue reliance on such statements. Many of
projections of the company regarding future events or future results, in contrast with
these risks are outside of the company’s control and could cause its actual results to
statements that reflect historical facts. Examples include discussion of the potential
differ materially from those it thought would occur. The forward-looking statements
efficacy of the company’s vaccine and treatment candidates and the company’s
included in this presentation are made only as of the date hereof. The company does
strategies, financing plans, growth opportunities and market growth. In some cases,
not undertake, and specifically declines, any obligation to update any such
you can identify such forward-looking statements by terminology such as “anticipate,”
statements or to publicly announce the results of any revisions to any such
“intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,”
statements to reflect future events or developments, except as required by law.
“would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or
similar expressions. Forward-looking statements are based on management’s current For further information, please reference the company’s reports and documents filed
beliefs and assumptions and on information currently available to the company. with the U.S. Securities and Exchange Commission (SEC). You may get these
However, these forward-looking statements are not a guarantee of the company’s documents by visiting EDGAR on the SEC website at www.sec.gov.
performance, and you should not place undue reliance on such statements.
CureVac Investor Presentation, July 2021 | 2
CureVac at a Glance
PIONEERS IN
MEDICAL MRNA
DEEP CLINICAL STRATEGIC
APPLICATIONS MANUFACTURING
PIPELINE PARTNERSHIPS
UNIQUE MRNA EXPERTISE
TECHNOLOGY
Development
Founded in 2000 support
Headquartered in Tübingen 3 GMP suites online Medical affairs
Prophylactic Vaccines expertise
>700 employees 1 large-scale suite
Immuno-oncology Commercial
in progress
Unmodified mRNA execution power
Protein Therapies
Broad European
Balanced immune
CMO network
activation
Flexible and mobile
Low dose activity
GMP units
CureVac Investor Presentation, July 2021 | 3
Differentiated Technology Creates A New Class of Products
FOCUS AREA LEAD PROGRAM / COLLABORATION FORMULATION
Prophylactic Vaccines COVID-19 CVnCoV
Induction of antibody responses COVID-19 CV2CoV Lipid nano-particle
Induction of T-cell responses Rabies CV7202
Oncology
Induction of T-cell responses Tumor-associated antigens
Lipid nano-particle
Immune Induction of antibody responses Shared neo-antigens
active Breaking of tolerance
applications
Activation of innate and adaptive immunity CV8102 Peptide based
Protein Therapy
Oncology
Genmab collaboration Lipid nano-particle
Use of the liver as a bioreactor
Convey controlled immunogenicity
Immune Rare Diseases
Harvard collaboration Polymer based
silent Ocular administration
applications Yale collaboration
Mucosal delivery
CRISPR collaboration Lipid nano-particle
Other
CureVac Investor Presentation, July 2021 | 4
CureVac Pipeline: A Diversified Portfolio
PRE-CLINICAL PRE-CLINICAL
AREA PROGRAMS AND INDICATIONS COLLABORATIONS DISCOVERY DEVELOPMENT PHASE 1 PHASE 2 PHASE 3
CVnCoV: COVID-19 (2) (1)
COVID-19 2nd-generation vaccines
PROPHYLACTIC CV7202: Rabies
VACCINES
Lassa, Yellow Fever
Disruptive low
dose technology Respirational Syncytial Virus
Other Infectious Diseases
Diverse projects
(Rota, Malaria, Universal Influenza)
CV8102: cMEL, ACC, SCC, HNSCC
ONCOLOGY BI13618409 (CV9202):
Non-Small Cell Lung Cancer
Vaccines and intra-
Shared neo-antigen
tumoral applications
Tumor Associated Antigens
Cas9 Gene-editing
PROTEIN
THERAPY Ocular Diseases
Rare diseases, gene Lung Respiratory Diseases
editing & antibodies
Therapeutic Antibodies
(1) Combined Phase 2b/3 clinical trial (2) Funding by CEPI provided for Phase 1 clinical trial, which has completed dosing and recruitment
CureVac Investor Presentation, July 2021 cMEL: Cutaneous melanoma; ACC: Adenoid cystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck | 5
2020 – Year of Corporate Transformation
Growing a commercial Expanding
organization Management expertise
EC
supply Strategic
agreement Strong cash position
Growing talent base: partnerships
with €1.32 billion*
>500 employees
Manufacturing
scaling-up
Accelerated clinical
development
Rigorous
pre-clinical
candidate
2020 $
Well financed to
drive business
Year of Corporate Transformation transformation
selection
CureVac Investor Presentation, July 2021 *As of December 31, 2020 EC: European Commission | 6
Propelling CureVac Forward
Building a commercial
organization
Developing
commercial products BIOPHARMA
Unique mRNA
technology
Strong science
BIOTECH
expertise
High operational
agility
CureVac Investor Presentation, July 2021 | 7
Partnering with GSK, the World’s Largest Vaccine Expert
Joint Development of Second-Generation mRNA Vaccines
VACCINE DEVELOPMENT EXPERTISE
Joint development of 2nd generation mRNA vaccines for rapid induction Vaccine
of improved immune responses with a favorable side effect profile development
expertise
Immune responses at low doses to support development of
multivalent vaccines as well as combination vaccines
Joint efforts to stay one step ahead of the pandemic with GSK
contributing resources to research, development and manufacturing
COMMERCIALIZATION ROLES
GSK to be Marketing Authorization Holder with exclusive rights
for development, manufacturing, and commercialization
CureVac to retain three commercial areas: Multivalent & International
Germany, Austria, Switzerland combination reach
vaccines
CureVac Investor Presentation, July 2021 | 8
CVnCoV, First-Generation COVID-19 Vaccine Candidate
Unmodified mRNA: Differentiated Mode of Action, Mimics Natural Immunity
Encoded protein
Ribosomes
Optimizing untranslated regions
based on potent, tissue-specific
Optimized regulatory elements
ribosome interaction
Targeted optimizations
Optimizations allow for increased
translation efficiency and
immunogenicity
mRNA construct
Maximizing ribosome interaction for
increased protein expression enables
low dose activity
5’ untranslated Open Reading Frame 3’ untranslated
region Protein coding portion region
CureVac Investor Presentation, July 2021 | 10Unique Mechanism of Action for Immunotherapy and Infectious Diseases
PROPHYLACTIC VACCINES
UNIQUE MECHANISM OF ACTION
Active at low dose in humans
Unmodified, natural mRNA
Enables multivalent vaccines
Inducing type I interferons
Fast, large-scale GMP production
Inducing B and T cell responses
Multiple product candidates
Activating innate immune system
Inducing boostable memory responses CANCER VACCINES &
IMMUNO-MODULATION
Innate and adaptive immune activation
Key activation of T cell responses
Demonstrated breaking of tolerance
Multiple product candidates
CureVac Investor Presentation, July 2021 | 11Clinical Development of COVID-19 Vaccine Candidate, CVnCoV
JUNE JULY AUGUST SEPTEMBER OCTOBER NOVEMBER DECEMBER 2021
Phase 1 Phase 2a Phase 2b/3 (HERALD)
Germany / Belgium Peru / Panama Europe / South America
DOSE ESCALATION TRIAL DOSE CONFIRMATION TRIAL SAFETY AND EFFICACY TRIAL
2-20µg, placebo controlled 6µg / 12µg, placebo controlled 12µg, placebo controlled
280 participants, fully recruited 674 participants, fully recruited ~40,000 participants, fully recruited
Expected data update: Expected data readout: Final data announcement:
Publication submitted Q3 2021 June 2021
CureVac Investor Presentation, July 2021 | 12HERALD Study: Geographically Diverse and Multi-Variant
Europe
~25%
of study population
The
Latin HERALD
America Study
~75%
of study population
~40,000
study participants
~35,000 age 18 to 60
~5,000 > age of 60
10
Countries
CureVac Investor Presentation, July 2021 | 13COVID-19 Reality: Variants of Concern Spreading in Europe and Latin America
Other incl.
EUROPE
Other incl. original strain
original strain Lambda
(C.37)
Lambda
(C.37) Delta
Delta (B.1.617.2)
(B.1.617.2) Gamma
Gamma (P.1, 501Y.V3)
(P.1, 501Y.V3) Beta
(B.1.351, 501Y.V2)
Beta Alpha
(B.1.351, 501Y.V2) (B.1.1.7, 501Y.V1)
Alpha
(B.1.1.7 / 501Y.V1)
SOUTH AMERICA
Countries where Phase 2b/3
trial is conducted
CureVac Investor Presentation, July 2021 *As of June 25, source: www.nextstrain.org / South America- or Europe-focused sub-sampling | 14HERALD Study: Efficacy Profile to Fight Pandemic and Variant Spread
IN THE AGE GROUP OF 18 TO 60
B.1 (wild type) A.2.5 B.1.429 (Epsilon) B.1.1.348
100%
B.1.1 (wild type)
PROTECTION AGAINST
B.1.111
HOSPITALIZATION OR DEATH
C.37 (Lambda) B.1.1.318
(0 vaccine vs. 6 placebo)
B.1.1.1 (wild type) B.1.526 P.2 (Zeta) N.5 B.1.177.73
PRIMARY
EFFICACY ENDPOINT
77%
B.1.1.7 (Alpha) B.1.623
PROTECTION AGAINST
MODERATE TO SEVERE DISEASE P.1.2 48%
B.1.621 (Colombia)
(9 vaccine vs. 36 placebo)
B.1.351 (Beta) B.1.160 B.1.1.519 (Mexico)
IN ALL AGE
GROUPS
C.36.3
53%
C.36 P.1 (Gamma) B.1.177 C.11 B.1.177.43
OVERALL VACCINE EFFICACY
B.1.177.53
(71 vaccine vs. 136 placebo)
B.1.617.2 (Delta) B.1.177.43 B.1.617.2 (Delta) B.1.236
CureVac Investor Presentation, July 2021 | 15HERALD Study: Variant Diversity Defines Basis for Efficacy in Final Analysis
TOTAL
B.1.621 Other
(Colombia) ~11%
~14% Wild type
~3%
LATIN AMERICA EUROPE
Lambda 204
Other ~21% adjudicated Alpha
B.1.621 ~13% Wild type cases ~92%
(Colombia) ~4% Alpha
~19% Delta
~32%
~1%
155 Alpha
~13%
Gamma 49 Gamma ~4%
adjudicated ~18% adjudicated
cases cases Delta ~2%
Lambda (~76%) (~24%) Other ~2%
~28% Gamma 15 different
~23% COVID-19 variants
CureVac Investor Presentation, July 2021 | 16HERALD Study: Variant Diversity in Overall Study Reflect New COVID-19 Reality
B.1 (wild type)
110
B.1.1 (wild type)
Belgium
B.1.1.1 (wild type)
B.1.1.7 (Alpha) EUROPE
B.1.351 (Beta) Germany
P.1 (Gamma) adjudicated +
B.1.617.2 (Delta) Spain non-adjudicated
B.1.429 (Epsilon)
C.37 (Lambda) cases
P.2 (Zeta) Netherlands
B.1.621 (Colombia)
B.1.1.519 (Mexico)
N.5
P.1.2
478
Dom. Rep.
A.2.5
B.1.111 LATIN AMERICA
B.1.526 Panama
B.1.623 adjudicated +
B.1.160
B.1.177
Mexico non-adjudicated
B.1.177.43 cases
B.1.1.348 Colombia
B.1.1.318
B.1.177.73 Argentina
29
C.11
C.36 virus strains
Peru
C.36.3 overall
B.1.177.53
B.1.236 0 50 100 150 200
Number of cases
CureVac Investor Presentation, July 2021 | 17HERALD Study: Balanced Trends for Efficacy Across Relevant Variants
EFFICACY BY STRAIN AGAINST ANY SEVERITY
(AGE GROUP OF 18 TO 60)
Variant CVnCoV Placebo VE LLCI ULCI
B.1.621 (Colombia) 11 17 42 -25 73
Other 7 13 51 -24 80
Gamma (P.1) 9 26 67 30 85
Lambda (C.37) 13 26 53 8 76
Alpha (B.1.1.7) 20 42 55 24 74
CureVac Investor Presentation, July 2021 VE: Vaccine efficacy; LLCI: Lower limit confidence interval; ULCI: Upper limit confidence interval | 18HERALD Study: Reactogenicity Data on 2,000 Vaccinated Trial Participants
SYSTEMIC LOCAL
SYMPTOMS Vaccination 1 Vaccination 2 SYMPTOMS Vaccination 1 Vaccination 2
Fatigue >60 Pain >60
18-60
18-60
Headache >60
18-60 Itching >60
>60
Myalgia 18-60
18-60
>60
>60 Swelling
Chills
18-60 18-60
>60
Arthralgia >60
18-60 Redness
>60 18-60
Fever 18-60
0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100%
>60
Percentage of Participants
Nausea 18-60
Grade 1
>60
Grade 2
Diarrhea 18-60
0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% Grade 3
Percentage of Participants
CureVac Investor Presentation, July 2021 | 19CVnCoV Preclinical Data:
Non-Human Primate Data Suggests CVnCoV Protection Against SARS-CoV-2
Humoral and cellular responses following SARS-CoV-2 challenge infection following
vaccination with 8µg vaccination with 8µg
Strong antibody induction UPPER RESPIRATORY TRACT:
NOSE AND THROAT
High titers of Spike (1.6 103) and Reduced viral load
RBD (3.2 103) binding antibodies
LOWER RESPIRATORY TRACT:
High titer of virus neutralizing antibodies LUNGS
(2.7 104 at peak) Full lung protection,
no detectable viruses
Generation of multiclonal T cell
responses in line with previous mouse data
Dose efficiency comparable to 12 µg dose
advanced into late-stage human clinical
testing
CureVac Investor Presentation, July 2021 *Full manuscript of pre-clinical data available on bioRxiv pre-print server | 20Delivering CVnCoV
Expanding European Manufacturing Network with Experienced Partners
Manufacturing partners
mRNA mRNA
production Fill & Finish Packaging
formulation
CureVac Investor Presentation, July 2021 | 22The RNA Printer®, Decentralized Mobile mRNA Production
RNA Printer® 2.0
pDNA mRNA
production production
PANDEMIC PREPAREDNESS
in hospitals in outbreak regions
CUSTOMIZED, POINT OF CARE
mRNA vaccines and therapeutics
CLINICAL DEVELOPMENT
acceleration at lower costs
CureVac Investor Presentation, July 2021 | 23Key Agreement with European Commission Delivering up to 405 million doses of CVnCoV to European member states Agreement for 225m doses and an additional 180m dose option €450 million upfront payment to mitigate project costs and help to de-risk production before regulatory approval Leveraging in-house manufacturing as well as integrated European manufacturing network CureVac Investor Presentation, July 2021 | 24
CV2CoV, Second-Generation COVID-19 Vaccine Candidate
Second-Generation Vaccines: New mRNA Backbone for Advanced Characteristics
Protein expression
2000
α Human anti SARS CoV s (CR3022)
Intracellular Cell surface
Untranslated regions
Geometric mean viable cells
Higher protein
expression 1500
Second- Balanced immune
generation response 1000
Improved kinetics
Poly-A tail 500
0
Gen 1 Gen 2 Gen 1 Gen 2
Joint development with GSK
CureVac Investor Presentation, July 2021 | 26CV2CoV Preclinical Data:
Faster Onset of Strong Immune Activation in Non-Human Primates
Preclinical Non-Human Primate (NHP) Model*
Neutralizing antibodies, Pseudovirus assay
CV2CoV, faster onset of neutralizing
antibody production. 211 titer two weeks
after first dose
~36x ~10x
Sham
Titer
10000 CVnCoV
Titer
CV2CoV CV2CoV, 10-times higher neutralizing
NAb
antibody induction of CV2CoV compared to
NAb
CVnCoV at peak level after 6 weeks
Pseudovirus
1000
Pseudovirus
100
Two-dose vaccination schedule of a
12µg dose on day 0 and day 28
10
0
1
2
4
5
6
8
Week of Study UNPUBLISHED DATA
CureVac Investor Presentation, July 2021 *Data generated in collaboration with Dan Barouch, Beth Israel Deaconess Medical Center, Harvard Medical School | 27CV2CoV / CVnCoV Preclinical Data:
Evidence of Protection Against South Africa Strain
Variant of Concern Efficient protection from challenge with B.1.351 by
B.1.351 (SA strain) vaccination with:
8µg of CVnCoV
Original strain
BavPat1 0.5-8µg CV2CoV
CENTRAL NERVOUS SYSTEM:
BRAIN
Survival Survival CVnCoV / Almost full protection,
non-vaccinated CV2CoV vaccinated B.1.351 close to limit of detection
BavPat1 20% BavPat1 100%
UPPER RESPIRATORY TRACT:
B.1.351 0% B.1.351 100% CONCHAE
Residual viral load
no statistical significance
Vaccinated animals were protected from disease
and mortality
LOWER RESPIRATORY TRACT:
TRACHEA, LUNGS
Robust induction of antibody titers for BavPat1, Almost full protection,
significantly lower antibody titers for B.1.351 B.1.351 close to limit of detection
CureVac Investor Presentation, July 2021 *Full manuscript of pre-clinical data available on bioRxiv pre-print server SA: South Africa | 28Oncology: Solid Tumor Lead Program, CV8102
Unique Mechanism of Action for Immunotherapy and Infectious Diseases
PROPHYLACTIC VACCINES
UNIQUE MECHANISM OF ACTION
Active at low dose in humans
Unmodified, natural mRNA
Enables multivalent vaccines
Inducing type I interferons
Fast, large-scale GMP production
Inducing B and T cell responses
Multiple product candidates
Activating innate immune system
Inducing boostable memory responses CANCER VACCINES &
INTRA-TUMORAL IMMUNOMODULATION
Innate and adaptive immune activation
Key activation of T cell responses
Demonstrated breaking of tolerance
Multiple product candidates
CureVac Investor Presentation, July 2021 | 30CV8102: From Local Immune Activation to Systemic Immune Responses
CV8102 targets immune
receptors TLR 7, TLR8 and RIG-I DRAINING LYMPH NODE
Activation of immune cells
Antigen presentation, T cell priming
TREATED TUMOR LESION NK, T- and B-cell activation
Induction of cytokines, chemokines
Antigen release and presentation
Activation of innate immune cells DISTAL TUMORS
NK and T-cell activation Tumor growth inhibition
Tumor growth inhibition Amplification of immune response
CureVac Investor Presentation, July 2021 NK cells: Natural killer cells | 31CV8102: Preliminary Efficacy Data Update
Preliminary data on overall tumor response and duration (data cut-off October 5, 2020)
Indication Dose Cohort A – single agent CV8102 Indication Dose Cohort C – CV8102 + anti-PD-1
HNSCC 100 µg * HNSCC 150 µg
cMEL 25 µg cMEL 600 µg Preliminary efficacy:
SCC 600 µg cMEL 600 µg
cMEL 450 µg cMEL 150 µg single agent
cMEL 150 µg cMEL 200 µg
ACC 150 µg cMEL 50 µg
ACC 300 µg cMEL 100 µg 1 Complete Response (cMel)
cMEL 150 µg cMEL 200 µg
* cMEL 450 µg
2 Partial Responses (cMel, cSCC)
ACC 150 µg
cMEL 300 µg 3 Stable Diseases with shrinkage of
cMEL 100 µg
cMEL 300 µg
ACC 900 µg injected and/or non-injected lesions*
cMEL 600 µg
ACC 900 µg HNSCC 25 µg
(HNSCC, Melanoma, cSCC)
SCC 900 µg
cMEL 50 µg
* cMEL 100 µg
HNSCC 600 µg
cMEL 900 µg cMEL 150 µg
cMEL 200 µg cMEL 450 µg
ACC 200 µg cMEL 900 µg Preliminary efficacy:
HNSCC 600 µg cMEL 900 µg
cMEL 200 µg
combination with PD-1
ACC 150 µg
cMEL 200 µg cMEL 50 µg antibodies
HNSCC 150 µg weeks
HNSCC 300 µg 1 Partial Response (cMel)
ACC 450 µg
2 Stable Diseases (cMel, HNSCC)
cMEL 200 µg
ACC 200 µg 55% pts anti-PD-1 pre-treated 86% pts anti-PD-1 pre-treated Patients more heavily pre-treated than
SCC 50 µg 7% with anti-CTLA4 48% pts with anti-CTLA4 patients in single agent cohort
cMEL 900 µg
SCC 200 µg
cMEL 900 µg
cMEL: Cutaneous melanoma; ACC: Adenoidcystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck
CureVac Investor Presentation, July 2021 | 32CV8102: Monotherapy Case Studies
Case study 1 Case study 2 Case study 3
150 µg Complete Response (CR) 100 µg CV8102 (SD) 450 µg CV8102 (PR)
Lesion 5 injections 8 injections Metastatic LN 6 injections 13 injections Pre-treatment after 8 CV8102
pre-treatment CV8102 CV8102 pre-treatment CV8102 CV8102 injections
Noninjected pleural lesion
74-year-old female patient, stage IIIc melanoma with 91-year-old male patient, stage IV HNSCC with large 50-year-old female patient, patient with anti-PD-1
multifocal in-transit metastases buccal and small lip lesion and a contralateral cervical refractory melanoma, stage IV N3c M1b at study entry,
metastatic LN, pretreated with cetuximab, external early progression on adjuvant Nivolumab treatment
CR of injected and non-injected cutaneous lesions
beam radiation and multiple surgeries
After 8 IT injections of CV8102
CR of subcutaneous lesion (MRI)
Buccal and lip lesions remained stable for 9 months
PR per RECIST 1.1 with shrinkage of injected and
Marked transient rise in serum IL-6 and CRP (study duration)
several non-injected lesions
following the first intra-tumoral injection
Untreated metastatic LN showed ongoing
Partial regression of injected tumor lesion after regression
800
5 injections
Overall stable disease according to RECIST 1.1
LDH [U/L]
CR of in-transit metastases on MRI, CR of all for 9 months 600
skin metastases at week 12 400
Early increase in IL-6
Patient continued to receive injections at monthly 200 Early drop in
intervals for 9 months without recurrence serum LDH
0
-20 -10 0 10 20 30 40 50 60 70 80
Trial day
CureVac Investor Presentation, July 2021 LN: Lymph node | 33Full-Year 2020 Financial Highlights
Our Financial Strength Enables the Company Transformation
Nasdaq listing: GSK
~€193 million €150 million
GSK Upfront
€120 million
KfW
€300 million Private Round:
~€560
million
€252 million Cash position
Cumulative
Investments
Grant of the German €110 million
~€1.32bn*
Federal Ministry of
Education and Research
Two mid-nine figure
€50 million 2021: ~$517.5m upfront Payments
1st tranche drawn of the European Commission
Aggregated gross proceeds
European Investment Bank (EIB) from public offering closed
February 2021
CureVac Investor Presentation, July 2021 *As of December 31, 2020 | 35Capital Inflow Fuels Corporate Transformation
+4,210%
€874m €50m
€35m
€200m
€4m €1.32bn
€120m
€579m
€30,7m
Full-year Full-year
Collaboration & Grants Finance rounds Loan Personnel 3rd Party Other
2019 upfront payments & equity expenses related cash-out 2020
CureVac Investor Presentation, July 2021 | 36Cash and Condensed Consolidated P&L Statement
Year ended December 31,
2020 2019
(in € millions) unaudited
Cash and Cash Equivalents 1,322.6 30.7
Year ended December 31, Three Month ended December 31,
2020 2019 2020 2019
(in € millions) unaudited unaudited
Revenue 48.9 17.4 6.0 6.8
Operating Expenses -158.7 -116.9 -52.6 -41.9
Operating Result -109.8 -99.5 -46.6 -35.1
Financial Result -20.0 -0.6 -10.7 -0.8
Earnings before Taxes (EBT) -129.8 -100.1 -57.3 -35.9
CureVac Investor Presentation, July 2021 | 37Executing on Corporate Growth With An Experienced Team
CureVac Management
Franz-Werner Haas Pierre Kemula Mariola Fotin-Mleczek Igor Splawski Antony Blanc, Malte Greune Klaus Edvardsen
LLD, LLM B.Sc. PhD PhD PhD PhD PhD*
Chief Executive Chief Financial Chief Technology Chief Scientific Chief Business/ Chief Operating
Chief Development
Officer Officer Officer Officer Commercial Officer Officer
Officer
NEW NEW
CureVac Investor Presentation, July 2021 *The appointment of Dr. Edvardsen will take effect on August 1, 2021 | 38CureVac Investor Relations Contact
Dr. Sarah Fakih
Vice President Corporate Communications
& Investor Relations
Friedrich-Miescher-Str. 15
72076 Tübingen
Germany
Phone: +49 (0)7071 9883 -1298
Mobile: +49 (0)160 90496949
Email: sarah.fakih@curevac.com
investors@curevac.com
CVAC | NasdaqListed https://www.linkedin.com/company/curevac/
@CureVac
https://twitter.com/CureVacRNA
CUSIP N2451R105 @CureVacRNA
ISIN NL0015436031
https://de-de.facebook.com/CureVac/
www.curevac.com
WKN A2P71U @CureVac
CureVac Investor Presentation, July 2021 | 39Appendix
© picture alliance/dpaCVnCoV Phase 1 Trial: Analysis of SARS-CoV-2 Specific Antibody Responses Binding antibodies: Measured by ELISA Spike protein (S1+S2) Receptor Binding Domaine (RBD) Virus neutralizing antibodies: Measured by micro-neutralization assay Live human SARS-CoV-2 virus Positive titers by 50% of neutralization Human Convalescent Sera (HCS) panel: Comparator with highest medical relevance 51 patients with multiple symptoms, 16 hospitalized Antibodies measured at the peak time CureVac Investor Presentation, July 2021 | 41
CVnCoV Phase 1 Trial: Design of the Study
Seronegative Seropositive Fully recruited
12µg 12µg Sentinel group (11) 24 4
8µg 8µg Full cohort 46 6
6µg 6µg / 46 10
4µg 4µg / 46 10
2µg 2µg Full cohort 46 10
Day 1 Day 29 Reported here: Total: Total:
Prime vaccination Boost vaccination Day 36 & 43 220 41
Partially blinded, placebo-controlled, dose-escalation study in healthy adults (18-60 years)
Clinical sites in Germany and Belgium
Intra-muscular vaccinations on day 1 and 29
Data Safety Monitoring Board (DSMB) approval of tolerability and dose escalation
CureVac Investor Presentation, July 2021 | 42CVnCoV Phase 1 Trial: Reactogenicity Data
No serious adverse events or dose limitations were observed
All symptoms were transient and resolved rapidly within 24 to 48 hours
Systemic symptoms Vaccination 1 Vaccination 2 Local symptoms Vaccination 1 Vaccination 2
2µg 2µg
8µg 8µg
Fatigue 12µg Pain 12µg
Placebo Placebo
2µg 2µg
Headache 8µg
12µg Itching 8µg
12µg
Placebo Placebo
2µg 2µg
Myalgia 8µg
12µg Swelling 8µg
12µg
Placebo Placebo
2µg 2µg
Chills 8µg
12µg
Redness 8µg
12µg
Placebo Placebo
2µg 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100%
Arthralgia 8µg
12µg Percentage of Participants
Placebo
2µg
Fever 8µg
12µg
Placebo
2µg
Nausea 8µg
12µg
Placebo
2µg
Grade 1
Diarrhea 8µg
Grade 2
12µg
Placebo
0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% Grade 3
Percentage of Participants
CureVac Investor Presentation, July 2021 | 43CVnCoV Phase 1 Trial: Spike Binding Antibodies
Dose-dependent induction of binding
antibodies across tested dose range
Immune response detected at
lowest dose of 2µg
Binding antibody titers reach highly
medically relevant HCS level at 12µg
CureVac Investor Presentation, July 2021 GMT: Geometric mean titer; HCS: Human convalescent sera Preliminary data | 44CVnCoV Phase 1 Trial: Neutralizing Antibodies
Titers remain stable after reaching
peak level
Immune response already
at lowest dose of 2µg detected
Neutralizing antibody titers reach highly
medically relevant HCS level at 12µg
CureVac Investor Presentation, July 2021 MN titers: Micro-neutralization titers; HCS: Human convalescent sera Preliminary data | 45CVnCoV Phase 1 Trial: Proportion of Neutralizing vs. Binding Antibodies
Quality of immune response is reflected in antibody ratios, which are similar
in CVnCoV-vaccinated subjects and convalescent patients
CVnCoV-vaccinated Virus-infected
Immunized individuals Convalescent patients
Ratio
Neutralizing
SPIKE antibodies
Binding
1.0
Neutralizing
RBD antibodies
Binding
1.0
CureVac Investor Presentation, July 2021 | 46CVnCoV Phase 1 Trial: Data for Seropositive Subjects
Long-lasting booster effect of neutralizing SARS-CoV-2 antibodies induced
with 2µg CVnCoV in seropositive subjects
Day 1 Day 29
2µg CVnCoV 2µg CVnCoV
CVnCoV vaccine was well tolerated in
seropositive subjects
All seropositive subjects benefited from
the vaccination
Stable antibody titers imply induction of
immune memory for long-term
protection
CureVac Investor Presentation, July 2021 Preliminary data | 47Unique Mechanism of Action Mediated by Interferon Type 1
In animal models… …and in humans
Rat model
Day 1 after 1 dose Induction of IFN- (all subjects)
20
(pg/ml)
2µg 8µg
15
Dose dependent
induction of 10
IFN- in rats
5
0
Day 1 2 8 29 30 36 1 2 8 29 30 36
Mouse model
Day 15 after 2nd dose
CureVac Investor Presentation, July 2021 | 48You can also read
